U.S. markets closed
  • S&P 500

    4,134.94
    -28.32 (-0.68%)
     
  • Dow 30

    33,821.30
    -256.33 (-0.75%)
     
  • Nasdaq

    13,786.27
    -128.50 (-0.92%)
     
  • Russell 2000

    2,188.21
    -43.79 (-1.96%)
     
  • Crude Oil

    62.61
    -0.77 (-1.21%)
     
  • Gold

    1,779.20
    +8.60 (+0.49%)
     
  • Silver

    25.88
    +0.04 (+0.15%)
     
  • EUR/USD

    1.2039
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • GBP/USD

    1.3942
    -0.0042 (-0.30%)
     
  • USD/JPY

    108.0700
    -0.0800 (-0.07%)
     
  • BTC-USD

    56,732.65
    +484.86 (+0.86%)
     
  • CMC Crypto 200

    1,292.89
    +58.47 (+4.74%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

Global Women's Health Therapeutics Market to Reach $23.3 Billion by 2027

ReportLinker
·24 min read

Abstract: - Global Women’s Health Therapeutics Market to Reach $23. 3 Billion by 2027. - Amid the COVID-19 crisis, the global market for Women’s Health Therapeutics estimated at US$10.

New York, April 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Women’s Health Therapeutics Industry" - https://www.reportlinker.com/p06033314/?utm_source=GNW
6 Billion in the year 2020, is projected to reach a revised size of US$23.3 Billion by 2027, growing at a CAGR of 11.9% over the analysis period 2020-2027. Postmenopausal Osteoporosis, one of the segments analyzed in the report, is projected to record a 14% CAGR and reach US$8.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hormonal Infertility segment is readjusted to a revised 9.9% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 16% CAGR
- The Women’s Health Therapeutics market in the U.S. is estimated at US$2.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2027 trailing a CAGR of 16% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.2% and 10.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.
- Polycystic Ovary Syndrome Segment to Record 10.3% CAGR
- In the global Polycystic Ovary Syndrome segment, USA, Canada, Japan, China and Europe will drive the 9.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.3 Billion in the year 2020 will reach a projected size of US$2.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.4 Billion by the year 2027, while Latin America will expand at a 11.7% CAGR through the analysis period.

- Select Competitors (Total 36 Featured) -

  • AstraZeneca

  • Bayer AG

  • Bristol-Myers Squibb Company

  • CooperSurgical, Inc.

  • Eli Lilly and Company

  • F. Hoffmann-La Roche Ltd

  • GlaxoSmithKline plc

  • Merck & Co., Inc.

  • Mylan N.V.

  • Novartis AG




Read the full report: https://www.reportlinker.com/p06033314/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Women’s Health
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Women’s Health Therapeutics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Women’s Health
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Postmenopausal
Osteoporosis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Postmenopausal Osteoporosis
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Postmenopausal
Osteoporosis by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Hormonal
Infertility by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Hormonal Infertility by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Hormonal Infertility by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Polycystic Ovary
Syndrome by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Polycystic Ovary Syndrome
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Polycystic Ovary
Syndrome by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 13: World Current & Future Analysis for Endometriosis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Endometriosis by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Endometriosis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Contraceptives by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Contraceptives by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Contraceptives by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Menopause by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Menopause by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Menopause by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 26: USA Historic Review for Women’s Health Therapeutics
by Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

CANADA
Table 28: Canada Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 29: Canada Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: Canada 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

JAPAN
Table 31: Japan Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: Japan Historic Review for Women’s Health Therapeutics
by Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: Japan 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

CHINA
Table 34: China Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 35: China Historic Review for Women’s Health Therapeutics
by Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: China 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

EUROPE
Table 37: Europe Current & Future Analysis for Women’s Health
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 38: Europe Historic Review for Women’s Health
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 39: Europe 15-Year Perspective for Women’s Health
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 40: Europe Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 41: Europe Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: Europe 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

FRANCE
Table 43: France Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: France Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 45: France 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

GERMANY
Table 46: Germany Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 47: Germany Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: Germany 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

ITALY
Table 49: Italy Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 50: Italy Historic Review for Women’s Health Therapeutics
by Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: Italy 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

UNITED KINGDOM
Table 52: UK Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 53: UK Historic Review for Women’s Health Therapeutics by
Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 54: UK 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

SPAIN
Table 55: Spain Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: Spain Historic Review for Women’s Health Therapeutics
by Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Spain 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

RUSSIA
Table 58: Russia Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 59: Russia Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 60: Russia 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 61: Rest of Europe Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Rest of Europe Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: Rest of Europe 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

ASIA-PACIFIC
Table 64: Asia-Pacific Current & Future Analysis for Women’s
Health Therapeutics by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 65: Asia-Pacific Historic Review for Women’s Health
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 66: Asia-Pacific 15-Year Perspective for Women’s Health
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 67: Asia-Pacific Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Asia-Pacific Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Asia-Pacific 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

AUSTRALIA
Table 70: Australia Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 71: Australia Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 72: Australia 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

INDIA
Table 73: India Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 74: India Historic Review for Women’s Health Therapeutics
by Application - Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: India 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

SOUTH KOREA
Table 76: South Korea Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 77: South Korea Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 78: South Korea 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

REST OF ASIA-PACIFIC
Table 79: Rest of Asia-Pacific Current & Future Analysis for
Women’s Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Rest of Asia-Pacific Historic Review for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: Rest of Asia-Pacific 15-Year Perspective for Women’s
Health Therapeutics by Application - Percentage Breakdown of
Value Sales for Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications for the Years
2012, 2020 & 2027

LATIN AMERICA
Table 82: Latin America Current & Future Analysis for Women’s
Health Therapeutics by Geographic Region - Argentina, Brazil,
Mexico and Rest of Latin America Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 83: Latin America Historic Review for Women’s Health
Therapeutics by Geographic Region - Argentina, Brazil, Mexico
and Rest of Latin America Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 84: Latin America 15-Year Perspective for Women’s Health
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Argentina, Brazil, Mexico and Rest of Latin
America Markets for Years 2012, 2020 & 2027

Table 85: Latin America Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Latin America Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Latin America 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

ARGENTINA
Table 88: Argentina Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: Argentina Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 90: Argentina 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

BRAZIL
Table 91: Brazil Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 92: Brazil Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Brazil 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

MEXICO
Table 94: Mexico Current & Future Analysis for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Mexico Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: Mexico 15-Year Perspective for Women’s Health
Therapeutics by Application - Percentage Breakdown of Value
Sales for Postmenopausal Osteoporosis, Hormonal Infertility,
Polycystic Ovary Syndrome, Endometriosis, Contraceptives,
Menopause and Other Applications for the Years 2012, 2020 &
2027

REST OF LATIN AMERICA
Table 97: Rest of Latin America Current & Future Analysis for
Women’s Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Rest of Latin America Historic Review for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: Rest of Latin America 15-Year Perspective for Women’s
Health Therapeutics by Application - Percentage Breakdown of
Value Sales for Postmenopausal Osteoporosis, Hormonal
Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications for the Years
2012, 2020 & 2027

MIDDLE EAST
Table 100: Middle East Current & Future Analysis for Women’s
Health Therapeutics by Geographic Region - Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 101: Middle East Historic Review for Women’s Health
Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia,
UAE and Rest of Middle East Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 102: Middle East 15-Year Perspective for Women’s Health
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of
Middle East Markets for Years 2012, 2020 & 2027

Table 103: Middle East Current & Future Analysis for Women’s
Health Therapeutics by Application - Postmenopausal
Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome,
Endometriosis, Contraceptives, Menopause and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 104: Middle East Historic Review for Women’s Health
Therapeutics by Application - Postmenopausal Osteoporosis,
Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis,
Contraceptives, Menopause and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033314/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001